Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

PolyTherics to develop novel biopharmaceutical molecule

PolyTherics : 27 January, 2010  (Special Report)
Leverton Licence Holdings (LLH), a wholly-owned subsidiary of CP2, is investing into a research programme to develop a novel biopharmaceutical molecule.
The research programme will be undertaken jointly by PolyTherics and Cantab BioPharmaceuticals, a wholly-owned subsidiary of CP2 based in Cambridge, UK.

PolyTherics will receive an upfront payment and ongoing technical support for the research, while LLH may elect to submit two further proteins for research under the collaboration. PolyTherics grants LLH an option to license products arising from the research collaboration, with PolyTherics receiving a share of any commercial returns. Further details of the agreement terms were not disclosed.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “We are delighted to establish a working relationship with CP2 and its subsidiaries Cantab and LLH through this new therapeutic programme. Importantly, as we embark as a company on the development of our own bio-better products, we are excited to share in the rewards of product commercialisation resulting from this new collaboration”.

Commenting on the investment, John Mayo, Managing Partner of CP2 said: “The next generation of biopharmaceuticals will need to deliver increased benefits to patients, physicians and healthcare systems over the original products. We believe that PEGylation will be a key technology in addressing this need. Our investment in this project furthers our strategy of investing in companies and projects with well-differentiated technologies. Our commercial, regulatory, drug development and manufacturing experience will increase both the probability of success and the value of the products developed with PolyTherics. The advanced PolyTherics technology has proven itself elsewhere in this field and we are looking forward to working with the team and replicating its successes in our programmes.”
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo